These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 9021406)

  • 1. Augmentation of immune response by an analog of the antigenic peptide in a human T-cell clone recognizing mutated Ras-derived peptides.
    Yokomizo H; Matsushita S; Fujisao S; Murakami S; Fujita H; Shirouzu M; Yokoyama S; Ogawa M; Nishimura Y
    Hum Immunol; 1997 Jan; 52(1):22-32. PubMed ID: 9021406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21.
    Abrams SI; Dobrzanski MJ; Wells DT; Stanziale SF; Zaremba S; Masuelli L; Kantor JA; Schlom J; Masuelle L [corrected to Masuelli L]
    Eur J Immunol; 1995 Sep; 25(9):2588-97. PubMed ID: 7589131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
    Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI
    Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA.
    Gedde-Dahl T; Spurkland A; Fossum B; Wittinghofer A; Thorsby E; Gaudernack G
    Eur J Immunol; 1994 Feb; 24(2):410-4. PubMed ID: 7507844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a murine mutant Ras CD8+ CTL peptide epitope variant that possesses enhanced MHC class I binding and immunogenic properties.
    Bristol JA; Schlom J; Abrams SI
    J Immunol; 1998 Mar; 160(5):2433-41. PubMed ID: 9498787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients.
    Qin H; Chen W; Takahashi M; Disis ML; Byrd DR; McCahill L; Bertram KA; Fenton RG; Peace DJ; Cheever MA
    Cancer Res; 1995 Jul; 55(14):2984-7. PubMed ID: 7606715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
    Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
    Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overlapping epitopes encompassing a point mutation (12 Gly-->Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells.
    Fossum B; Gedde-Dahl T; Hansen T; Eriksen JA; Thorsby E; Gaudernack G
    Eur J Immunol; 1993 Oct; 23(10):2687-91. PubMed ID: 7691613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of linear and branched peptide forms (MAPs) in the induction of T helper responses to point-mutated ras immunogens.
    Schott ME; Wells DT; Schlom J; Abrams SI
    Cell Immunol; 1996 Dec; 174(2):199-209. PubMed ID: 8954620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of peptide superagonists for a self-K-ras-reactive CD4+ T cell clone using combinatorial peptide libraries and mass spectrometry.
    Tanaka Y; Ohyama H; Ogawa M; Nishimura Y; Matsushita S
    J Immunol; 1999 Jun; 162(12):7155-61. PubMed ID: 10358161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell clones specific for p21 ras-derived peptides: characterization of their fine specificity and HLA restriction.
    Gedde-Dahl T; Fossum B; Eriksen JA; Thorsby E; Gaudernack G
    Eur J Immunol; 1993 Mar; 23(3):754-60. PubMed ID: 8449222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer.
    Kubuschok B; Neumann F; Breit R; Sester M; Schormann C; Wagner C; Sester U; Hartmann F; Wagner M; Remberger K; Schilling M; Pfreundschuh M
    Clin Cancer Res; 2006 Feb; 12(4):1365-72. PubMed ID: 16489095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell responses against products of oncogenes: generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides.
    Gedde-Dahl T; Eriksen JA; Thorsby E; Gaudernack G
    Hum Immunol; 1992 Apr; 33(4):266-74. PubMed ID: 1639630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
    Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered peptide ligands of islet autoantigen Imogen 38 inhibit antigen specific T cell reactivity in human type-1 diabetes.
    Geluk A; van Meijgaarden KE; Roep BO; Ottenhoff TH
    J Autoimmun; 1998 Aug; 11(4):353-61. PubMed ID: 9776713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
    Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
    Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of natural antigenic peptides of a human gastric signet ring cell carcinoma recognized by HLA-A31-restricted cytotoxic T lymphocytes.
    Suzuki K; Sahara H; Okada Y; Yasoshima T; Hirohashi Y; Nabeta Y; Hirai I; Torigoe T; Takahashi S; Matsuura A; Takahashi N; Sasaki A; Suzuki M; Hamuro J; Ikeda H; Wada Y; Hirata K; Kikuchi K; Sato N
    J Immunol; 1999 Sep; 163(5):2783-91. PubMed ID: 10453022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope.
    Sotiriadou R; Perez SA; Gritzapis AD; Sotiropoulou PA; Echner H; Heinzel S; Mamalaki A; Pawelec G; Voelter W; Baxevanis CN; Papamichail M
    Br J Cancer; 2001 Nov; 85(10):1527-34. PubMed ID: 11720440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minor structural changes in a mutated human melanoma antigen correspond to dramatically enhanced stimulation of a CD4+ tumor-infiltrating lymphocyte line.
    Sundberg EJ; Sawicki MW; Southwood S; Andersen PS; Sette A; Mariuzza RA
    J Mol Biol; 2002 May; 319(2):449-61. PubMed ID: 12051920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR.
    Doherty DG; Penzotti JE; Koelle DM; Kwok WW; Lybrand TP; Masewicz S; Nepom GT
    J Immunol; 1998 Oct; 161(7):3527-35. PubMed ID: 9759873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.